<p>Silence Therapeutics plc has filed an amendment to its previously issued Form 8-K, disclosing the material terms of a compensation arrangement with interim principal executive officer Iain Ross and the Board committee appointments of James Ede-Golightly. No other changes were made to the original filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-328684), on December 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

<p>Silence Therapeutics plc amended its Form 8-K to disclose CEO Iain Ross's compensation and board appointments for James Ede-Golightly. No other changes were made to the original filing.</p>

Silence Therapeutics Amends 8-K to Disclose CEO Compensation and Board Appointments